Supporting veterinarians with compliant access to critical therapeutics and global treatment options

VMD Sciences (VMDS) recently announced expanded efforts to support large animal veterinarians facing increasing therapeutic constraints due to an ongoing reported U.S. shortage of Buscopan® (N-butylscopolammonium bromide) in the United States. Beyond addressing veterinarian reported supply gaps, VMDS is also prioritizing the response to emerging infectious disease threats including Theileriosis spread by the Asian longhorned tick.

To address the current domestic shortage of equine colic therapies, VMDS is supporting veterinarians by providing a compliant pathway to import Buscopan® Compositum Solution for Injection. This EU-approved alternative allows equine practitioners to maintain continuity of care for colic management and related conditions. By bridging the gap between domestic supply and clinical demand, VMDS helps ensure that practitioners are not clinically restricted by domestic treatment supply.

In parallel, the expansion of the Asian longhorned tick across multiple U.S. regions has introduced urgent clinical challenges, specifically the rise of infectious diseases, including Theileriosis. As emerging threats become increasingly relevant to North American herd health management, VMDS is proactively expanding its oversight to ensure broader therapeutic preparedness. By supporting access to antiparasitic and associated treatments that are licensed in other countries, VMDS empowers practitioners to manage emerging threats that currently lack domestic solutions.

VMDS helps veterinarians leverage established regulatory pathways to support access to medications licensed in other countries, bridging critical gaps in treatment. By helping navigate the regulatory and logistical complexities of international importation, VMDS facilitates veterinarian access to international manufacturers and licensed distributors to improve supply continuity for essential veterinary medications.

“Our goal is to ensure veterinarians are never placed in a position where patient care is delayed or compromised due to supply shortages or emerging disease pressures,” said Ricky Falcha, President of VMD Sciences. “Large animal practice depends on consistent access to proven, effective therapies, and we are committed to responsibly expanding those options while helping maintain the highest standards of regulatory compliance.”

VMDS emphasizes that all global veterinary medicine distribution and sourcing efforts are conducted in accordance with importation regulations and requirements, with emphasis on compliance, safety, and traceability.

As supply chain volatility and vector-borne disease risks continue to evolve, VMDS remains committed to supporting the large animal and entire veterinary community with responsive, compliant, and globally informed therapeutic access solutions.

About VMD Sciences

VMD Sciences is the innovative leader in veterinary regulatory and pharmaceutical services, dedicated to safely accelerating global access to biomedical treatments for animals. Headquartered in Austin, Texas, the company specializes in Managed Access Programs, compliant importation pathways, and solutions for drug shortages, enabling veterinarians to deliver advanced therapies that might otherwise be unavailable.

By partnering with pharmaceutical innovators, researchers, and veterinary practices, VMD Sciences helps vets bridge regulatory barriers to expand treatment options, support clinical studies, and improve outcomes for animals. Learn more at vmdsciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520536732/en/

“Our goal is to ensure veterinarians are never placed in a position where patient care is delayed or compromised due to supply shortages or emerging disease pressures”